Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10689705 | 0.91 | ALDH1A1 (0.66) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL7487588 | 0.85 | MEN1 (0.55) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL7035542 | 0.83 | MEN1 (0.52) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL20522828 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL16166137 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL14156161 | 0.81 | KMT2A (0.46) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL8269762 | 0.80 | ITGB3 (0.48) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL16166500 | 0.79 | MEN1 (0.62) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL16166235 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL3218987 | 0.79 | HPGD (0.48) | ALDH1A1MAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2489665-B1 | Evaluation probe for central nervous system permeability, evaluation method for central nervous system permeability, and screening method using an evaluation probe for central nervous system permeability | CANON KK (JP) | 2019-10-02 | — | — | EP | disclosed |
| US-10227337-B2 | Evaluation probe for central nervous system permeability, evaluation method for central nervous system permeability, and screening method using an evaluation probe for central nervous system permeability | CANON KABUSHIKI KAISHA (JP) | 2019-03-12 | — | — | US | disclosed |
| EP-2601194-B1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-8871929-B2 | Fused-imidazoyl compounds useful as antimicrobial agents | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| EP-2601194-A2 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2489665-A1 | Evaluation probe for central nervous system permeability, evaluation method for central nervous system permeability, and screening method using an evaluation probe for central nervous system permeability | Canon Kabushiki Kaisha (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-20120207683-A1 | EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, EVALUATION METHOD FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, AND SCREENING METHOD USING AN EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY | CANON KABUSHIKI KAISHA (JP) | 2012-08-16 | — | — | US | disclosed |
| WO-2012018662-A2 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPS4Y1 | ALDH1A1 2376/4885MAPT 4607/4885MEN1 1050/4885 |
| US-10227337-B2 | Evaluation probe for central nervous system permeability, evaluation method for central nervous system permeability, and screening method using an evaluation probe for central nervous system permeability | PMP22, GAP43, AQP4 | ALDH1A1 976/4885MAPT 378/4885MEN1 2553/4885 |
| US-20120207683-A1 | EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, EVALUATION METHOD FOR CENTRAL NERVOUS SYSTEM PERMEABILITY, AND SCREENING METHOD USING AN EVALUATION PROBE FOR CENTRAL NERVOUS SYSTEM PERMEABILITY | PMP22, GAP43, AQP4 | ALDH1A1 976/4885MAPT 378/4885MEN1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.